Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 304

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 8
Chunk 304
---
 plans and other8 — 35 1,153 — — — 1,188 Change in noncontrolling interest— — — — — — 2 2 Balance at December 31, 20241,765 $18 $(8,201)$21,333 $(7,900)$(1,925)$39 $3,364 

The accompanying notes are an integral part of these consolidated financial statements.

2024 Form 10-K   |  54

AbbVie Inc. and Subsidiaries

Consolidated Statements of Cash Flows years ended December 31 (in millions) (brackets denote cash outflows)202420232022Cash flows from operating activitiesNet earnings$4,286 $4,873 $11,845 Adjustments to reconcile net earnings to net cash from operating activities:Depreciation764 752 778 Amortization of intangible assets7,622 7,946 7,689 Deferred income taxes(1,449)(2,889)(1,931)Change in fair value of contingent consideration liabilities3,771 5,128 2,761 Payments of contingent consideration liabilities(1,995)(870)(164)Stock-based compensation911 747 671 Acquired IPR&D and milestones2,757 778 697 Gain on divestitures— — (172)Non-cash litigation reserve adjustments, net of cash payments508 (443)2,243 Impairment of intangible assets4,476 4,229 770 Other, net(63)(225)(150)Changes in operating assets and liabilities, net of acquisitions:Accounts receivable207 66 (1,455)Inventories(319)(417)(686)Prepaid expenses and other assets361 (188)(264)Accounts payable and other liabilities177 3,840 1,769 Income tax assets and liabilities, net(3,208)(488)542 Cash flows from operating activities18,806 22,839 24,943 Cash flows from investing activitiesAcquisition of businesses, net of cash acquired(17,493)— (255)Other acquisitions and investments(3,024)(1,223)(539)Acquisitions of property and equipment(974)(777)(695)Purchases of investment securities(73)(77)(1,438)Sales and matur